Companies Dominating the Mesenchymal Stem Cells Landscape
- Bio-Techne Corporation
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Merck KGaA
- Genlantis, Inc.
- Celprogen Corporation
- PromoCell GmbH
- Cyagen US Inc.
- Plus Therapeutics, Inc.
- Human Longevity, Inc.
- Thermo Fisher Scientific Inc.
- Pluristem Therapeutics Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
Mesenchymal Stem Cells Market in 2025 is assessed at USD 4.39 billion.
The global market size was valued at around USD 3.93 billion in 2024 and is projected to grow at a CAGR of more than 14.7%, reaching USD 23.37 billion revenue by 2037.
Asia Pacific is set to attain largest share by 2037, driven by increasing awareness about healthcare and improving healthcare facilities, along with rising cancer and cardiovascular diseases in the region.
The major players in the market include Bio-Techne Corporation, Merck KGaA, Genlantis, Inc., Celprogen Corporation, PromoCell GmbH, Cyagen US Inc., Plus Therapeutics, Inc., Human Longevity, Inc., Thermo Fisher Scientific Inc., Pluristem Therapeutics Inc.